JPM lineup: New roles across industry

Dozens of companies and investment firms announced management moves in the run-up to the J.P. Morgan Healthcare Conference in San Francisco this week, with new CEOs being announced at multiple biotechs, including Argenx. 

After nearly 18 years at Argenx SE (Euronext:ARGX; NASDAQ:ARGX), co-founder Tim Van Hauwermeiren is moving from CEO to chairman of the biotech. COO Karen Massey, who joined the Belgian biotech three years ago from the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) will succeed him. ...